BACKGROUND/AIMS: Relapses of @entity30 are difficult to predict. We assessed the value of serum level of @entity650 , @entity5 necrosis factor alpha ( @entity310 ) and soluble TNF receptors as predictors of relapse in quiescent @entity30 . @entity1 /METHODS: Thirty-six @entity1 with inactive @entity30 , treated or not, were included. Various clinical and biological parameters, including @entity650 , @entity310 and soluble TNF receptors serum levels were measured at inclusion in the study and the @entity1 were followed clinically for 1 year. The relapse was defined as a @entity30 Activity Index (CDAI) greater than 150 with an increase greater than 100 compared to the inclusion value. We analysed the ability of these parameters to predict relapse in parallel to clinical characteristics and other laboratory parameters. RESULTS: Among the 32 variables tested, @entity650 serum level had the greatest ability to predict the time-to-relapse, with 17-fold chance of relapse over a 1-year period for @entity1 with an @entity650 serum level greater than 20 pg/ml than for @entity1 with a lower level (P < 0.001). A high serum level of the soluble TNF receptors @entity10736 and @entity10733 also had significant predictive value, in contrast to @entity310 serum levels. An @entity650 serum level greater than 20 pg/ml and either an acid alpha-1-glycoprotein level greater than 1.1 g/l or a soluble interleukin-2 receptor serum level greater than 95 pM/l were risk factors selected by a stepwise multivariate analysis. In both models a good prognosis group was defined by the absence of the two risk factors, a bad prognostic group by the presence of the two risk factors and an intermediate in between. With both models, the good prognosis group included 17 @entity1 who experienced no relapse over the 1-year follow-up, whereas all @entity1 (seven with the first model and six with the second) in the bad prognosis group had a relapse during the follow-up. Looking specifically at two homogeneous subgroups including either naturally/ @entity2983 ( @entity3504 ) quiescent or corticoid quiescent @entity1 , a very good predictive value for @entity650 serum concentration was also found. CONCLUSION: @entity650 serum level alone or in association with other biological parameters such as acid alpha-1-glycoprotein or the soluble interleukin-2 receptor serum level may be useful for predicting the course of the disease in @entity1 with quiescent @entity30 .

A high serum concentration of @entity650 is predictive of relapse in quiescent XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity650 :: ('3569', 'Gene') :: ['Interleukin-6', 'interleukin-6'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity310 :: ('7124', 'Gene') :: ['TNF-alpha'] @entity10733 :: ('7133', 'Gene') :: ['p75'] @entity3504 :: ('CHEBI:6775', 'Chemical') :: ['5-ASA'] @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's Disease", "Crohn's disease"] @entity2983 :: ('MESH:D019804', 'Chemical') :: ['5-aminosalicylic acid'] @entity10736 :: ('7132', 'Gene') :: ['p55']
@entity30 :: (MESH:D003424,Disease) :: ['Crohn's disease']
